

# Jonathan S Serody

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9368370/publications.pdf>

Version: 2024-02-01

134  
papers

13,198  
citations

44444

50  
h-index

29333

108  
g-index

134  
all docs

134  
docs citations

134  
times ranked

20091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 1255-1263.	2.5	26
2	B Cell Function in the Tumor Microenvironment. <i>Annual Review of Immunology</i> , 2022, 40, 169-193.	9.5	84
3	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
4	BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. <i>Blood</i> , 2022, 139, 2983-2997.	0.6	6
5	Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
6	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	0.6	8
7	Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. <i>Blood</i> , 2021, 137, 3306-3309.	0.6	26
8	Targeted therapy of human leukemia xenografts in immunodeficient zebrafish. <i>Scientific Reports</i> , 2021, 11, 5715.	1.6	15
9	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). <i>Melanoma Research</i> , 2021, 31, 162-172.	0.6	6
10	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 616-629.	2.6	41
11	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	84
12	Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD. <i>Blood Advances</i> , 2021, 5, 4578-4589.	2.5	9
13	Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells. <i>Journal of Immunology</i> , 2021, 207, 2598-2607.	0.4	10
14	Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 5925-5928.	2.5	19
15	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3794-3804.	0.8	235
16	Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 858.	1.8	16
17	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020, 135, 28-40.	0.6	14
18	Pathogenic Bhlhe40+ GM-CSF+ CD4+ T cells promote indirect alloantigen presentation in the GI tract during GVHD. <i>Blood</i> , 2020, 135, 568-581.	0.6	35

#	ARTICLE	IF	CITATIONS
19	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. <i>Journal of Clinical Investigation</i> , 2020, 130, 3051-3068.	3.9	90
20	Alternative tumour-specific antigens. <i>Nature Reviews Cancer</i> , 2019, 19, 465-478.	12.8	206
21	B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. <i>Cell</i> , 2019, 179, 1191-1206.e21.	13.5	291
22	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. <i>Blood</i> , 2019, 134, 1670-1682.	0.6	49
23	Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. <i>Cancer Immunology Research</i> , 2019, 7, 1591-1604.	1.6	48
24	Chemokines and Graft-Versus-Host Disease. , 2019, , 323-347.		0
25	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. <i>Journal of Immunology</i> , 2019, 202, 2795-2805.	0.4	10
26	Targeting PI3K $\hat{\imath}$ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	2.6	9
27	Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 391-397.	2.0	10
28	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	0.6	21
29	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019, 4, .	2.3	8
30	A Dual Immunotherapy Nanoparticle Improves T $\hat{\imath}$ Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	11.1	130
31	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	6.6	3,706
32	A critical role for donor-derived IL-22 in cutaneous chronic GVHD. <i>American Journal of Transplantation</i> , 2018, 18, 810-820.	2.6	45
33	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018, 8, 304-319.	7.7	255
34	Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. <i>Blood Advances</i> , 2018, 2, 2307-2319.	2.5	15
35	Combination Immunotherapy: A Dual Immunotherapy Nanoparticle Improves T $\hat{\imath}$ Cell Activation and Cancer Immunotherapy ( <i>Adv. Mater.</i> 25/2018). <i>Advanced Materials</i> , 2018, 30, 1870182.	11.1	4
36	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	128

#	ARTICLE	IF	CITATIONS
37	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 4804-4820.	3.9	210
38	The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 4604-4621.	3.9	32
39	Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. <i>PLoS ONE</i> , 2018, 13, e0193832.	1.1	74
40	A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 250-262.	3.2	159
41	Targeting the Canonical Nuclear Factor- $\kappa$ B Pathway with a High-Potency IKK2 Inhibitor Improves Outcomes in a Mouse Model of Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 569-580.	2.0	8
42	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- $\beta$ production. <i>Blood</i> , 2017, 129, 2570-2580.	0.6	122
43	T-cell expression of AhR inhibits the maintenance of pTreg cells in the gastrointestinal tract in acute GVHD. <i>Blood</i> , 2017, 130, 348-359.	0.6	25
44	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. <i>Blood</i> , 2017, 130, 2131-2145.	0.6	37
45	Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 877-882.	15.6	541
46	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	2.3	53
47	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 3472-3483.	3.9	130
48	Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. <i>Journal of Clinical Investigation</i> , 2017, 127, 2441-2451.	3.9	37
49	Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 1813-1825.	3.9	84
50	Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V&epsilon; <sup>TM</sup> DJer. <i>Bioinformatics</i> , 2016, 32, 3729-3734.	1.8	59
51	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016, 128, 1013-1017.	0.6	95
52	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw144.	3.0	271
53	A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2016, 126, 3541-3555.	3.9	30
54	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81

#	ARTICLE	IF	CITATIONS
55	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. <i>Blood</i> , 2015, 126, 1621-1628.	0.6	104
56	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	0.6	101
57	GVHD and miR: good things in small packages. <i>Blood</i> , 2015, 126, 1265-1267.	0.6	5
58	Peptide/MHC Tetramer-Based Sorting of CD8+ T Cells to a Leukemia Antigen Yields Clonotypes Drawn Nonspecifically from an Underlying Restricted Repertoire. <i>Cancer Immunology Research</i> , 2015, 3, 228-235.	1.6	16
59	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , 2015, 125, 3335-3346.	0.6	55
60	Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2129-2135.	2.0	14
61	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	3.9	173
62	Altered T cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease. <i>European Journal of Immunology</i> , 2014, 44, 1662-1671.	1.6	5
63	Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3818-3829.	3.2	230
64	Effectiveness of an Algorithm-Based Approach to the Utilization of Plerixafor in Patients Undergoing Chemotherapy-Based Stem Cell Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1064-1068.	2.0	16
65	C-C Chemokine Receptor 5 on Pulmonary Mesenchymal Cells Promotes Experimental Metastasis via the Induction of Erythroid Differentiation Regulator 1. <i>Molecular Cancer Research</i> , 2014, 12, 274-282.	1.5	8
66	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	0.6	179
67	Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD. <i>Blood</i> , 2014, 123, 1604-1614.	0.6	24
68	Increased BCR responsiveness in B cells from patients with chronic GVHD. <i>Blood</i> , 2014, 123, 2108-2115.	0.6	86
69	CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4266-4280.	3.9	173
70	Chemokines and graft-versus-host disease. , 2013, , 393-424.		6
71	One Is Better than Two: TCR Pairing and GVHD. <i>Science Translational Medicine</i> , 2013, 5, 188fs21.	5.8	2
72	Circulating Fibrocytes Prepare the Lung for Cancer Metastasis by Recruiting Ly-6C+ Monocytes Via CCL2. <i>Journal of Immunology</i> , 2013, 190, 4861-4867.	0.4	81

#	ARTICLE	IF	CITATIONS
73	CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. <i>Blood</i> , 2013, 122, 825-836.	0.6	58
74	Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. <i>Blood</i> , 2013, 122, 2125-2134.	0.6	47
75	Aryl Hydrocarbon Receptor Deficient Donor T Cells Display Decreased Migration and Cause Reduced Or Enhanced Graft-Versus-Host Diseases In Different Transplant Models. <i>Blood</i> , 2013, 122, 4477-4477.	0.6	0
76	Attenuation of Acute Graft-versus-Host Disease in the Absence of the Transcription Factor ROR $\gamma$ t. <i>Journal of Immunology</i> , 2012, 189, 1765-1772.	0.4	48
77	Bacterial sepsis and GI tract GVHD: more commensal than you think. <i>Blood</i> , 2012, 120, 6-7.	0.6	14
78	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. <i>Blood</i> , 2012, 120, 2529-2536.	0.6	126
79	The IL-17 Differentiation Pathway and Its Role in Transplant Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S56-S61.	2.0	74
80	Bone Marrow B cell Precursor Number after Allogeneic Stem Cell Transplantation and GVHD Development. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 968-973.	2.0	34
81	Infusional Mitoxantrone Plus Bolus Melphalan as a Stem Cell Transplant Conditioning Regimen for Multiple Myeloma. <i>Cancer Investigation</i> , 2011, 29, 214-219.	0.6	8
82	TH17 Cells, Proteins Associated with TH17 Polarization, and Their Role in Graft vs. Host Disease. , 2011, , 341-365.		0
83	Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 141-146.	2.0	43
84	Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. <i>Blood</i> , 2011, 117, 3268-3276.	0.6	143
85	Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT $\alpha$ CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. <i>Pediatric Blood and Cancer</i> , 2011, 57, 499-505.	0.8	11
86	Bone Marrow Stromal Cells Inhibit Apoptosis of Chronic Lymphocytic Leukemia Cells (CLL) by Expressing Erythroid Differentiation Regulator 1 (ERDR1). <i>Blood</i> , 2011, 118, 1764-1764.	0.6	1
87	Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies. <i>Blood</i> , 2011, 118, 1940-1940.	0.6	0
88	The Immunosuppressive Tumor Environment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice. <i>Journal of Immunotherapy</i> , 2010, 33, 482-491.	1.2	13
89	Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. <i>Blood</i> , 2010, 115, 4914-4922.	0.6	52
90	Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. <i>Blood</i> , 2010, 116, 5738-5747.	0.6	384

#	ARTICLE	IF	CITATIONS
91	L-Selectin Is Dispensable for T Regulatory Cell Function Postallogeneic Bone Marrow Transplantation. <i>American Journal of Transplantation</i> , 2010, 10, 2596-2603.	2.6	7
92	The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2010, 70, 10161-10169.	0.4	139
93	Alloimmune Retinopathy Associated with Antibodies to Transducin- $\beta$ as a Complication of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 135-138.	2.0	2
94	Attenuated Acute Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation In the Absence of ROR $\gamma$ t. <i>Blood</i> , 2010, 116, 3742-3742.	0.6	0
95	Erythroid Differentiation Regulator 1 (ERDR1) From Nurse-Like Cells Promotes the Survival of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2010, 116, 1372-1372.	0.6	0
96	Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. <i>Leukemia and Lymphoma</i> , 2009, 50, 741-748.	0.6	5
97	Ex vivo Inhibition of NF- $\kappa$ B Signaling in Alloreactive T-cells Prevents Graft-Versus-Host Disease. <i>American Journal of Transplantation</i> , 2009, 9, 452-462.	2.6	15
98	Intravesicular Cidofovir for the Management of BK Virus-Associated Cystitis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 391-392.	2.0	28
99	In vitro "differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. <i>Blood</i> , 2009, 113, 1365-1374.	0.6	272
100	Pulmonary Stromal Cells Expressing CC-Chemokine Receptor 5 Promote Metastasis Via Erythroid Differentiation Regulator 1. <i>Blood</i> , 2009, 114, 3601-3601.	0.6	2
101	C-C Chemokine Receptor 5 on Pulmonary Fibrocytes Facilitates Migration and Promotes Metastasis via Matrix Metalloproteinase 9. <i>American Journal of Pathology</i> , 2008, 173, 253-264.	1.9	57
102	The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. <i>Leukemia and Lymphoma</i> , 2008, 49, 1860-1869.	0.6	20
103	Reactivation of Cytomegalovirus Infection in Critically Ill Immunocompetent Patients. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2367.	3.8	10
104	TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. <i>Blood</i> , 2008, 112, 3508-3516.	0.6	75
105	Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. <i>Blood</i> , 2007, 109, 1307-1315.	0.6	107
106	Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). <i>Blood</i> , 2007, 110, 3480-3488.	0.6	72
107	Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. <i>Vaccine</i> , 2007, 25, 6604-6612.	1.7	34
108	CD200 is induced by ERK and is a potential therapeutic target in melanoma. <i>Journal of Clinical Investigation</i> , 2007, 117, 3922-9.	3.9	88

#	ARTICLE	IF	CITATIONS
109	CD62L Is Not Critical for T Regulatory Cell-Mediated Protection from Lethal Acute GVHD.. Blood, 2007, 110, 2178-2178.	0.6	1
110	Diagnosis and Treatment of Chronic Graft-Versus-Host Disease. Seminars in Hematology, 2006, 43, 70-80.	1.8	35
111	Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.. Blood, 2006, 108, 2945-2945.	0.6	0
112	C-C Chemokine Receptor 5 on Stromal Cells Promotes Pulmonary Metastasis. Cancer Research, 2005, 65, 3374-3379.	0.4	50
113	Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood, 2005, 105, 2249-2257.	0.6	44
114	Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood, 2005, 105, 3372-3380.	0.6	113
115	Leukocyte migration and graft-versus-host disease. Blood, 2005, 105, 4191-4199.	0.6	287
116	Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood, 2005, 106, 3300-3307.	0.6	227
117	A Novel Viral System for Generating Antigen-Specific T Cells. Journal of Immunology, 2005, 175, 3431-3438.	0.4	40
118	Cytoprotection by Amifostine during Autologous Stem Cell Transplantation for Advanced Refractory Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2005, 11, 1022-1030.	2.0	14
119	Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning. Journal of Immunology, 2004, 173, 845-854.	0.4	124
120	Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8120-8125.	3.3	238
121	CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease. Journal of Immunology, 2004, 173, 2933-2941.	0.4	77
122	A Novel System for Simultaneous in Vivo Tracking and Biological Assessment of Leukemia Cells and ex Vivo Generated Leukemia-Reactive Cytotoxic T Cells. Cancer Research, 2004, 64, 3914-3921.	0.4	29
123	Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunology, Immunotherapy, 2004, 53, 777-785.	2.0	31
124	Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anti-Cancer Drugs, 2004, 15, 453-459.	0.7	41
125	In vivo imaging of graft-versus-host-disease in mice. Blood, 2004, 103, 3590-3598.	0.6	132
126	L-Selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood, 2004, 104, 3804-3812.	0.6	324



#	ARTICLE	IF	CITATIONS
127	The effect of oral mucositis on morbidity and mortality in bone marrow transplant. <i>Seminars in Oncology</i> , 2003, 30, 76-83.	0.8	50
128	An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 443-452.	2.0	10
129	Host Absence of CCR5 Potentiates Dendritic Cell Vaccination. <i>Journal of Immunology</i> , 2003, 170, 4201-4208.	0.4	32
130	Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 $\beta$ (CCL3) after allogeneic BMT in mice. <i>Blood</i> , 2003, 101, 3714-3721.	0.6	34
131	T-lymphocyte production of macrophage inflammatory protein-1 $\beta$ is critical to the recruitment of CD8+ T cells to the liver, lung, and spleen during graft-versus-host disease. <i>Blood</i> , 2000, 96, 2973-2980.	0.6	127
132	T Cell Activity After Dendritic Cell Vaccination Is Dependent on Both the Type of Antigen and the Mode of Delivery. <i>Journal of Immunology</i> , 2000, 164, 4961-4967.	0.4	80
133	Murine T Lymphocytes Incapable of Producing Macrophage Inhibitory Protein-1 $\alpha$ Are Impaired in Causing Graft-Versus-Host Disease Across a Class I But Not Class II Major Histocompatibility Complex Barrier. <i>Blood</i> , 1999, 93, 43-50.	0.6	40
134	PREVENTION OF INFECTIONS IN BONE MARROW TRANSPLANT RECIPIENTS. <i>Infectious Disease Clinics of North America</i> , 1997, 11, 459-477.	1.9	32